Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Shares Sold by Graphene Investments SAS

Graphene Investments SAS cut its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 14.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,600 shares of the specialty pharmaceutical company's stock after selling 3,600 shares during the quarter. Graphene Investments SAS's holdings in Jazz Pharmaceuticals were worth $2,557,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Versant Capital Management Inc raised its holdings in shares of Jazz Pharmaceuticals by 9.4% in the first quarter. Versant Capital Management Inc now owns 1,058 shares of the specialty pharmaceutical company's stock worth $131,000 after buying an additional 91 shares during the period. Bessemer Group Inc. grew its holdings in shares of Jazz Pharmaceuticals by 0.3% in the fourth quarter. Bessemer Group Inc. now owns 26,932 shares of the specialty pharmaceutical company's stock worth $3,317,000 after purchasing an additional 92 shares during the last quarter. Synovus Financial Corp increased its stake in Jazz Pharmaceuticals by 0.5% in the 4th quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company's stock worth $2,365,000 after buying an additional 100 shares during the period. Quarry LP lifted its holdings in Jazz Pharmaceuticals by 6.3% during the 4th quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company's stock valued at $209,000 after buying an additional 100 shares in the last quarter. Finally, Quadrant Capital Group LLC boosted its position in Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after buying an additional 101 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Down 0.6%

Shares of NASDAQ JAZZ traded down $0.61 during mid-day trading on Friday, reaching $106.90. 871,418 shares of the company were exchanged, compared to its average volume of 827,221. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06. The firm has a 50-day moving average of $108.55 and a 200 day moving average of $119.66. The stock has a market cap of $6.47 billion, a price-to-earnings ratio of 14.25, a P/E/G ratio of 4.62 and a beta of 0.33. The company has a quick ratio of 2.97, a current ratio of 3.38 and a debt-to-equity ratio of 1.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The firm had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. During the same period in the previous year, the company posted $2.68 earnings per share. The business's quarterly revenue was down .5% compared to the same quarter last year. On average, research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the business's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total transaction of $185,625.00. Following the sale, the chief executive officer now owns 440,307 shares of the company's stock, valued at approximately $54,487,991.25. The trade was a 0.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Seamus Mulligan purchased 100,000 shares of the firm's stock in a transaction on Friday, May 9th. The stock was bought at an average cost of $98.26 per share, with a total value of $9,826,000.00. Following the acquisition, the director now owns 100,000 shares of the company's stock, valued at approximately $9,826,000. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have sold 3,000 shares of company stock valued at $355,925 in the last ninety days. Corporate insiders own 4.30% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on JAZZ. UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and lifted their price target for the company from $145.00 to $179.00 in a research note on Friday, March 7th. Truist Financial raised their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. HC Wainwright lifted their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research report on Monday, March 10th. Royal Bank Of Canada dropped their price target on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Finally, Wall Street Zen lowered Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $184.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.